Genetics Co. Raises $191M In Venture Funding
Maze Therapeutics, a company focused on translating genetic research into new medicines, said Thursday it has raised $191 million in venture capital led by investments from Third Rock Ventures and ARCH...To view the full article, register now.
Already a subscriber? Click here to view full article